ReviewLaryngoscope investigative otolaryngology2022
Clinical outcomes of multifocal papillary thyroid cancer: A systematic review and meta-analysis.
Review in Laryngoscope investigative otolaryngology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.
- 2025 American Thyroid Association Management Guidelines for Adult Patients with Differentiated Thyroid Cancer.Thyroid : official journal of the American Thyroid Association · 2025Guideline
- Validation of the 2025 ATA risk stratification system in a cohort of patients with papillary thyroid carcinoma.The Journal of clinical endocrinology and metabolism · 2026Observational
- Unveiling the true impact of dominant thyroid nodules: are they really the Culprits?Surgery today · 2026Article
- Mechanisms of Yiguanjian Decoction against Thyroid Cancer: A Network-Based Pharmacological Investigation.Chinese journal of integrative medicine · 2026Article
- Predictive models for contralateral occult thyroid carcinoma and central lymph node metastasis in unilateral multifocal papillary thyroid carcinoma based on ultrasound.Quantitative imaging in medicine and surgery · 2026Article
- Preoperative circulating tumor cells level is associated with lymph node metastasis in patients with unifocal papillary thyroid carcinoma.World journal of surgical oncology · 2025Article
- Analysis of the clonal origin and differences in the biological behavior of multifocal papillary thyroid carcinoma.Oncology letters · 2024Article
- FBXO2 promotes the progression of papillary thyroid carcinoma through the p53 pathway.Scientific reports · 2024Article
- Incomplete ablation of thyroid cancer: Achilles' Heel?BMC endocrine disorders · 2024Article
- Multi-UniFocality (MUF), in contrast to multifocality, in thyroid lesions: Relation to lymphocytic thyroiditis.Pathology international · 2024Article
- Bilaterality, not multifocality, is an independent risk factor for recurrence in low-risk papillary thyroid cancer.Journal of the National Cancer Institute · 2023Article
- Should multifocality be an indication for prophylactic neck dissection in papillary thyroid cancer?Updates in surgery · 2023Article
- Association between thyroid stimulating hormone levels and papillary thyroid cancer risk: A meta-analysis.Open life sciences · 2023Article
- Clinical outcomes of multifocal papillary thyroid cancer: A systematic review and meta-analysis.Laryngoscope investigative otolaryngology · 2022Review
- Unilateral Multifocality Is Not a Risk Factor for Recurrence After Thyroid Lobectomy: A Study of 1,684 Patients With Differentiated Thyroid Cancer.In vivo (Athens, Greece)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Papillary thyroid cancer (PTC) is the most common endocrine malignancy with a steadily increasing incidence. Researches have reported that tumor multifocality occurs in an extensive number of cases. Nevertheless, the clinical characteristics and prognostic value remained controversial. This study was performed to investigate the relationship between multifocal PTC and adverse clinicopathologic features and the prognosis. Methods: A systematic review and meta-analysis were conducted based on three electronic databases up to December 31, 2021. Parameters of interest included five clinical features (extrathyroidal extension, lymphovascular invasion, central lymph node metastasis, lateral lymph node metastasis, distant metastasis) and were pooled into risk ratios (RRs). Time-to-event data (recurrence-free survival and all-cause mortality) were evaluated using hazard ratios (HRs). Publication bias was examined using funnel plots and Egger's test. Results: A total of 23 articles were included according to the inclusion criteria; all of the studies were retrospective cohorts. In comparison with unifocality, multifocality showed an increased risk of extrathyroidal extension (RR 1.38, 95% CI 1.25-1.53), lymphovascular invasion (RR 1.27, 95% CI 1.04-1.55), central lymph node metastasis (RR 1.21, 95% CI 1.12-1.30), lateral lymph node metastasis (RR 1.86, 95% CI 1.62-2.14), and distant metastasis (RR 1.35, 95% CI 1.03-1.76). Multifocal patients were predisposed to postoperative recurrence (HR 1.76, 95% CI 1.50-2.07). The rate of all-cause mortality did not reach a statistical difference. Level of Evidence: 2. Conclusion: Multifocal PTC is more aggressive in contrast to unifocal PTC and is accompanied by an increased risk of recurrence. They were usually diagnosed in higher grades and stages. To achieve the maximal benefit, we recommend personalized therapy and close follow-up for multifocal PTC patients. Further prospective studies will clarify the best-fitted treatment plans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.